Oncoprint representing distribution of oncogenic and variants of uncertain significance (VUS) from archival tumour tissue.
Cohort 1 with niraparib monotherapy (No significant association was detected between clinical benefit and IHC markers (PTEN, p53, MMR, PDL-1), or NGS (We tested the feasibility of assessing HRR in the baseline ctDNA samples from EC using a custom NGS panel. Baseline blood sample for ctDNA analysis was available in 26 patients (C1 